T1	Participants 59 97	cetuximab-associated acnelike eruption
T2	Participants 315 344	cetuximab-related facial rash
T3	Participants 362 434	24 patients with metastatic colorectal cancer with cetuximab facial rash
T4	Participants 1211 1255	patients with cetuximab-related facial rash.
